Dementia and Geriatric Cognitive Disorders
Original Research Article
CSF-Tau and CSF-Aβ1–42 in Posterior Cortical AtrophyBaumann T.P.a, b · Duyar H.b · Sollberger M.a, b · Kuhle J.b · Regeniter A.c · Gomez-Mancilla B.d · Schmidtke K.e · Monsch A.U.aaMemory Clinic – Neuropsychology Center, Departments of Geriatrics, bDepartment of Neurology, and cCSF Laboratory, University Hospital, and dNeurosciences, NS Discovery, Novartis Pharma AG, Basel, Switzerland; eCenter for Geriatric Medicine and Gerontology, University Hospital Freiburg, Freiburg, Germany
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Accepted: April 29, 2010
Published online: July 01, 2010
Issue release date: July 2010
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 2
ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)
For additional information: https://www.karger.com/DEM
Abstract
Objective: Our purpose was to measure Aβ1–42, T-tau and P-tau181 in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer’s disease (AD). Methods: CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits. Results: The Aβ1–42, T-tau and P-tau181 levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD. Conclusion: High T-tau and P-tau181 and low Aβ1–42 levels in PCA – typically observed in AD – indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.
© 2010 S. Karger AG, Basel
Related Articles:
References
- Benson DF, Davis RJ, Snyder BD: Posterior cortical atrophy. Arch Neurol 1988;45:789–793.
- Mendez MF, Ghajarania M, Perryman KM: Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer’s disease. Dement Geriatr Cogn Disord 2002;14:33–40.
- Schmidtke K, Hüll M, Talazko J: Posterior cortical atrophy: variant of Alzheimer’s disease? A case series with PET findings. J Neurol 2005;252:27–35.
- Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knopman DS, Petersen RC: Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168–1174.
- Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR: Focal cortical presentations of Alzheimer’s disease. Brain 2007;130:2636–2645.
- Ng SY, Villemagne VL, Masters CL, Rowe CC: Evaluating atypical dementia syndromes using positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 2007;64:1140–1144.
- Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ: Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696–1702.
- Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelsø C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nägga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K: Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 2001;47:1776–1781.
- Taiki K, Yumiko M, Kenji I, Nobutaka H: Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex. J Neurol 2010;257:469–471.
- Wolf RC, Schönfeldt-Lecuona C: Depressive symptoms as first manifestation of posterior cortical atrophy. Am J Psychiatry 2006;163:939–940.
- Peskind ER, Rieske R, Quinn JF, et al: Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005;19:220–225.
- Renner JA, Burns JM, Hou CE, McKeel DW Jr, Storandt M, Morris JC: Progressive posterior cortical dysfunction: a clinicopathological series. Neurology 2004;63:1175–1180.
- Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O: Longitudinal study of CSF biomarkers in patients with Alzheimer’s disease. PLoS One 2009;4:e6294.
Article / Publication Details
Accepted: April 29, 2010
Published online: July 01, 2010
Issue release date: July 2010
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 2
ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)
For additional information: https://www.karger.com/DEM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
